Petros Pharmaceuticals Q4 EPS $(2.17) Misses $(1.11) Estimate, Sales $364.25K Miss $1.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Petros Pharmaceuticals reported a Q4 EPS of $(2.17), missing the $(1.11) estimate by 95.5%, and sales of $364.25K, missing the $1.55M estimate by 76.5%. This represents a decrease in performance compared to the same period last year.
April 02, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Petros Pharmaceuticals reported significantly lower Q4 earnings and sales than expected, missing estimates by a wide margin.
The substantial miss in both earnings per share and sales compared to analyst estimates, along with a year-over-year decline in performance, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100